Finasteride vs Oral Minoxidil: Head-to-Head Efficacy for Hair Loss

Why These Two Drugs Get Compared So Often

Finasteride and oral minoxidil are the two most commonly prescribed systemic treatments for androgenetic alopecia (AGA) in men. Both are taken once daily as a pill, making them natural alternatives for patients who want a simple oral regimen instead of topical solutions. The comparison intensified after low-dose oral minoxidil gained popularity as an off-label option around 2017 to 2020.

AGA affects approximately 50% of men by age 50, according to epidemiologic data reviewed by the American Academy of Dermatology. For decades, finasteride 1 mg was the only oral medication with FDA approval for this condition. Topical minoxidil had been available over the counter since 1988, but compliance was poor because of twice-daily application, scalp irritation, and greasy residue. When dermatologists began prescribing oral minoxidil at low doses (typically 2.5 mg or less for men), patients gained a second pill option. That shift forced a practical question: which oral therapy produces better regrowth?

The short answer is that the two drugs are not interchangeable. They target different pathways, carry different risk profiles, and may even work best in different AGA patterns. Choosing between them requires matching the drug's mechanism to the patient's biology.

How Finasteride Works: Blocking DHT at the Source

Finasteride inhibits the type II 5-alpha reductase enzyme, reducing conversion of testosterone to dihydrotestosterone (DHT) in the scalp and serum. A 1 mg daily dose lowers serum DHT by approximately 70% and scalp DHT by roughly 64%, based on pharmacokinetic data from the original FDA review [1].

DHT is the primary androgen responsible for follicular miniaturization in genetically susceptible hair follicles. By cutting DHT levels, finasteride slows or halts the miniaturization process. This makes it primarily an anti-loss drug, though many patients also see regrowth, particularly at the vertex.

The Kaufman et al. 5-year extension study (N=1,553) demonstrated that men on finasteride 1 mg maintained a mean increase of 277 hairs in a 5.1 cm² target area at year 5, while placebo-treated men lost 139 hairs over the same period [1]. That net difference of 416 hairs in a small scalp zone is clinically visible. The study also showed that efficacy peaked around year 2 and then gradually declined but remained significantly above baseline through year 5.

Dr. Ken Washenik, then at NYU Langone, noted in a commentary on the Kaufman data: "Finasteride's real value is in what it prevents. The hair you keep is often more important than the hair you grow."

One limitation: finasteride is less effective in the temporal region and along the frontal hairline, where type I 5-alpha reductase predominates. Dutasteride, which blocks both type I and type II isoenzymes, may outperform finasteride in frontal AGA, but that comparison falls outside this article's scope.

How Oral Minoxidil Works: Stimulating Growth Directly

Oral minoxidil is a prodrug. After ingestion, the liver converts it to minoxidil sulfate via the sulfotransferase enzyme SULT1A1. Minoxidil sulfate then opens ATP-sensitive potassium channels in vascular smooth muscle and in dermal papilla cells. The result is vasodilation, increased perifollicular blood flow, and prolongation of the anagen (growth) phase of the hair cycle. It also appears to upregulate vascular endothelial growth factor (VEGF) expression in dermal papilla cells, per research published in the Journal of Investigative Dermatology [3].

Unlike finasteride, oral minoxidil does not alter androgen signaling. It is a pure growth stimulant. This distinction matters: oral minoxidil can thicken existing hairs and recruit resting follicles into active growth, but it does not address the underlying hormonal driver of AGA.

Sinclair's 2018 retrospective review documented improved hair density in patients taking oral minoxidil at doses ranging from 0.25 mg to 5 mg daily [2]. Most male patients responded at 2.5 mg daily, while women often required only 0.25 to 1.25 mg daily. The response was dose-dependent, with higher doses producing greater density gains but also more side effects.

A 2022 systematic review and meta-analysis by Randolph and Tosti (N=634 across 17 studies) confirmed that low-dose oral minoxidil (LDOM) improved hair growth outcomes across multiple forms of alopecia, including AGA, telogen effluvium, and alopecia areata [4]. The pooled response rate was approximately 60 to 65% for AGA patients, though study designs varied.

Efficacy Comparison: What the Evidence Actually Shows

No published phase III randomized controlled trial has directly compared finasteride 1 mg to oral minoxidil in AGA. Clinicians must rely on cross-trial comparisons, which carry inherent limitations in population matching, outcome measures, and follow-up duration.

Here is what indirect evidence suggests when comparing the two drugs across key dimensions:

Hair count and density. Finasteride has stronger long-term data. The Kaufman 5-year study used standardized macrophotography with validated hair counts [1]. Oral minoxidil studies are mostly retrospective or open-label, with shorter follow-up periods (6 to 12 months). Both drugs produce clinically meaningful improvement, but finasteride's evidence base is deeper and more rigorous.

Onset speed. Both drugs typically require 3 to 6 months before visible change. Some patients on oral minoxidil report earlier shedding (a "dread shed" phenomenon), which may occur within the first 4 to 8 weeks as telogen hairs are pushed out by new anagen hairs. This temporary shedding also happens with finasteride but is reported less frequently.

Durability. Finasteride's effects have been tracked for up to 10 years in extension studies. Hair counts decline after year 2 but remain above baseline through year 5 and, in most patients, through year 10 [1]. Oral minoxidil's long-term durability data is limited. Most published follow-up extends only 12 to 24 months.

Region of best response. Finasteride performs best at the vertex (crown). Oral minoxidil appears to benefit both the vertex and the frontal/temporal zones, since its mechanism is not androgen-dependent. For patients with primarily frontal thinning, oral minoxidil may offer an advantage, though head-to-head frontal data is lacking.

Combination potential. The two drugs target different pathways, making them logical combination partners. A retrospective study by Jimenez-Cauhe et al. found that adding oral minoxidil 2.5 mg to finasteride 1 mg produced greater improvement than either drug alone in men with AGA [5]. The combination approach is gaining traction in clinical practice.

Side-Effect Profiles: Different Risks, Different Conversations

The side effects of finasteride and oral minoxidil are distinct enough that they often drive drug selection more than efficacy data does.

Finasteride side effects. The most discussed risks involve sexual function. In the Kaufman trial, 1.8% of finasteride-treated men reported decreased libido (vs. 1.3% placebo), and 1.3% reported erectile dysfunction (vs. 0.7% placebo) [1]. These rates are low but not zero, and the topic generates significant anxiety among younger patients. A controversial entity called "post-finasteride syndrome" has been reported in case series, though the American Urological Association and other bodies have not recognized it as a distinct clinical condition [6]. Depression and mood changes have been reported at rates similar to placebo in controlled trials.

Oral minoxidil side effects. The primary concern is cardiovascular. Minoxidil was originally developed as an antihypertensive at doses of 10 to 40 mg daily. At low doses used for hair loss (0.25 to 5 mg), the cardiovascular risk is reduced but not eliminated. Reported effects include:

• Hypertrichosis (unwanted hair growth on the face, arms, or body) in up to 15 to 20% of patients at 2.5 mg daily
• Peripheral edema and fluid retention
• Lightheadedness or postural hypotension
• Tachycardia (rare at low doses)
• Pericardial effusion (extremely rare at LDOM doses, but documented at higher antihypertensive doses)

A safety review by Panchaprateep and Lueangarun reported that cardiovascular events at doses of 5 mg or below were uncommon but recommended baseline ECG and blood pressure monitoring for patients with pre-existing cardiac conditions [7].

Hypertrichosis is the most frequently reported side effect in practice. For women, it can be cosmetically unacceptable at doses above 1.25 mg daily. For men, it tends to be mild (increased body hair) and sometimes considered a neutral or even positive effect.

Who Should Choose Finasteride

Finasteride is the stronger first-line option for men with vertex-predominant AGA who want a single oral medication with long-term safety data. The ideal finasteride candidate is a man in his 20s to 40s with early-to-moderate AGA (Norwood II to V), no history of depression or sexual dysfunction, and a preference for a well-studied, FDA-approved drug.

Finasteride is not approved for use in women of reproductive potential due to teratogenic risk (category X). Postmenopausal women have been prescribed finasteride off-label, but the evidence in female pattern hair loss is mixed. A Cochrane review concluded that finasteride shows limited benefit in women compared to men [8].

Patients who are anxious about sexual side effects may not be good candidates. The nocebo effect in finasteride trials is well-documented: in a study by Mondaini et al., men informed about potential sexual side effects reported them at 3x the rate of men who were not informed, despite receiving the same drug [9].

Who Should Choose Oral Minoxidil

Oral minoxidil fits patients who cannot tolerate finasteride, prefer to avoid 5-alpha reductase inhibitors, or have frontal-predominant thinning where finasteride's effects are weaker. It is also the default oral option for women with AGA, since finasteride is contraindicated in women who may become pregnant.

Good candidates for oral minoxidil include:

• Women with female pattern hair loss (Ludwig classification I to III)
• Men who experienced sexual side effects on finasteride
• Patients with poor compliance on topical minoxidil who want the same drug in oral form
• Patients with diffuse thinning or thinning that extends beyond the vertex

Oral minoxidil requires more baseline screening than finasteride. Patients should have blood pressure checked, and those with a history of heart failure, valvular disease, or pericardial effusion need cardiology clearance. An ECG at baseline is reasonable for patients over 50 or those with cardiovascular risk factors.

The dose should start low. Most dermatologists begin men at 2.5 mg daily and women at 0.625 to 1.25 mg daily, titrating based on response and side effects over 3 to 6 months.

Combination Therapy: Using Both Drugs Together

Because finasteride and oral minoxidil target entirely different pathways, using them together is pharmacologically rational. Finasteride slows the hormonal destruction of follicles. Oral minoxidil stimulates the remaining follicles to grow thicker and longer.

The Jimenez-Cauhe retrospective analysis showed that men on finasteride 1 mg plus oral minoxidil 2.5 mg had greater improvement in global photography scores than men on either drug alone [5]. The combination was well-tolerated, with side-effect rates similar to oral minoxidil monotherapy.

Combination therapy is becoming the standard approach for moderate-to-severe AGA in many dermatology practices. Dr. Antonella Tosti of the University of Miami has stated: "For male patients with Norwood IV or higher, I almost always start with both finasteride and low-dose oral minoxidil. Waiting to add the second drug means losing time and potentially losing follicles that cannot be recovered."

The downside of combination therapy is cost (two prescriptions), the additive side-effect burden, and difficulty attributing any side effect to a specific drug. Some clinicians prefer to start one drug, assess response at 6 months, and add the second only if results are insufficient.

Switching Between Finasteride and Oral Minoxidil

Patients sometimes need to switch from one drug to the other. The most common scenario is a man on finasteride who develops sexual side effects and wants to transition to oral minoxidil. Less commonly, a patient on oral minoxidil switches to finasteride due to bothersome hypertrichosis.

Switching is not smooth. Because finasteride's benefit comes from DHT suppression, stopping it allows DHT to return to baseline within approximately 2 weeks, and hair loss resumes at the pre-treatment rate. Patients should expect a shedding phase 2 to 4 months after discontinuing finasteride.

Conversely, stopping oral minoxidil leads to a telogen shift as stimulated follicles return to their resting state. This shedding can be abrupt and emotionally distressing.

The safest transition approach is to overlap the two drugs for 3 to 6 months: start the new drug while still taking the old one, then taper off the original medication after the new drug has had time to take effect. This overlap strategy minimizes the "gap" period of accelerated shedding.

Cost and Access Considerations

Finasteride 1 mg is available as a generic and costs $5 to $15 per month in most US pharmacies. Insurance coverage varies; many plans cover it for AGA, though some classify it as cosmetic.

Oral minoxidil is also available as a generic (minoxidil tablets are manufactured for hypertension) and costs roughly $10 to $30 per month depending on dose and pharmacy. Because its use for hair loss is off-label, insurance coverage is inconsistent. Some compounding pharmacies offer lower doses (0.25 mg, 0.625 mg, 1.25 mg) that are not commercially available as scored tablets.

Both drugs are among the most affordable prescription options in dermatology. Cost is rarely the deciding factor between them.

Monitoring and Follow-Up

Finasteride monitoring is minimal. No routine blood work is required, though some clinicians check baseline PSA in men over 40 because finasteride lowers PSA by approximately 50%, which can mask prostate cancer detection on screening tests. The FDA label recommends doubling a measured PSA value in men on finasteride to estimate the true level [10].

Oral minoxidil monitoring should include blood pressure at baseline and at follow-up visits. Patients with cardiac risk factors should have a baseline ECG. Weight should be tracked to detect fluid retention early. Heart rate monitoring is reasonable for the first 3 months.

Both drugs should be assessed photographically at baseline and at 6 and 12 months. Standardized global photography (vertex, frontal, and temporal views under consistent lighting) remains the best way to document response. Hair counts and trichoscopy add objectivity but are not always available in general dermatology practice.

Finasteride 1 mg produces an average serum DHT reduction of 70% at steady state, with hair count benefits maintained above baseline for at least 5 years in the majority of responders [1]. Oral minoxidil at 2.5 mg daily improves hair density in approximately 60 to 65% of AGA patients within 6 to 12 months [4].